Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (VNDA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
vnda · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Vanda Pharmaceuticals Inc. (VNDA) measures how much investors pay for each dollar of the company's trailing earnings. VNDA's current PE ratio of N/A is calculated by dividing its stock price of $5.94 by its TTM earnings per share of -$4.03.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 8 fiscal years · Front-end computedMinQ1 · 25%33.7x
MedianQ3 · 75%96.5x
Max
At N/A, VNDA's current P/E is lower than in 0% of its annual fiscal year readings over the past 8 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Vanda Pharmaceuticals Inc.You VNDA | $357M | N/A | — | -$4.03 |
 Achieve Life Sciences, Inc. ACHV | $563M | N/A | — | -$1.25 |
 Allogene Therapeutics, Inc. ALLO | $451M | N/A | — | -$0.87 |
 Arcturus Therapeutics Holdings Inc. ARCT | $202M | N/A | — | -$2.40 |
 Atea Pharmaceuticals, Inc. AVIR | $346M | N/A | — | -$1.94 |
 Capricor Therapeutics, Inc. CAPR | $1.2B | N/A | — | -$2.26 |
 Humacyte, Inc. HUMA | $232M | N/A | — | -$0.26 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.74 | — | |
2024-12-31 FY2024 | — | $-0.33 | — | |
2023-12-31 FY2023 | 96.51x | $0.04 | +45.1% | |
2022-12-31 FY2022 | 66.49x | $0.11 | +152.9% | |
2021-12-31 FY2021 | 26.29x | $0.60 | -14.2% | |
2020-12-31 FY2020 | 30.65x | $0.43 | +306.1% | |
2019-12-31 FY2019 | 7.55x | $2.17 | -85.7% | |
2018-12-31 FY2018 | 52.72x | $0.50 | — | |
2017-12-31 FY2017 | — | $-0.35 | — | |
2016-12-31 FY2016 | — | $-0.41 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Vanda Pharmaceuticals Inc. (VNDA) measures how much investors pay for each dollar of the company's trailing earnings. VNDA's current PE ratio of N/A is calculated by dividing its stock price of $5.94 by its TTM earnings per share of -$4.03.
Frequently asked questions
VNDA pe ratio · 6 questionsVNDA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $5.94 and TTM EPS of -$4.03. Data sourced from Financial Modeling Prep via VNDA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vanda Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08